MabPlex is a leading contract development and manufacturing organization (CDMO) offering end-to-end services from gene sequence to finished biopharmaceutical product. With expertise in monoclonal (including bispecific) antibodies, antibody-drug conjugates and other recombinant proteins, we can accelerate your projects at every step, including cell line development, upstream and downstream process development, and formulation development – with fully compliant GMP operations. With three state-of-the-art sites in Yantai, Shanghai and San Diego, we have the facilities and expertise to support our clients globally. At MabPlex, we are committed to delivering high-quality product on-time with exceptional value.

Development

CMO cGMP Manufacturing

ADCs Analytical Solutions

QMS Quality and Regulatory

09sepAll DayBPI EastSeptember 9-12, 2019
Boston, MA
Visit us at booth 1107

MabPlex International Announces Appointment of Dr. Wei Chen (Ph.D) as Chief Executive Officer

August 11, 2019
MabPlex International Ltd (MabPlex) has appointed Wei Chen Ph.D as the company's new Chief Executive Officer (CEO). Dr. Chen, a...
Read More

MabPlex Manufactured Monoclonal Antibody Receives IND Approval from the U.S. Food and Drug Administration

January 17, 2019
MabPlex International, Ltd, a global Contract Development and Manufacturing Organization (CDMO ) offering services in the development and manufacturing of...
Read More

MabPlex M2 Commercial Manufacturing Facility Opening Ceremony

November 6, 2018
Jianmin Fang, PhD (Chairman of MabPlex International Ltd.) highlighted the development and growth of MabPlex over the past five years...
Read More
X
INFORMATION